Imricor Medical Systems Inc (ASX: IMR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Imricor Medical Systems Inc Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Imricor Medical Systems Inc (ASX: IMR)
Latest News
Healthcare Shares
Here's why the Imricor Medical (ASX:IMR) share price is surging 8% today
Healthcare Shares
Imricor Medical (ASX:IMR) share price spikes 6% after expanding trial sites
Share Market News
Why the Imricor (ASX:IMR) share price is racing 6% higher today
Healthcare Shares
Imricor (ASX:IMR) share price rises on latest update
Share Market News
Why the Imricor (ASX:IMR) share price is edging higher today
IMR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Imricor Medical Systems Inc
Imricor Medical Systems Inc is a medical device company engaged in addressing issues with traditional x-ray-guided ablation procedures through the development of MRI-guided technology. The products of the company include Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter and Vision-MR Dispersive Electrode.
IMR Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
28 Mar 2024 | $0.56 | $0.02 | 3.67% | 62,954 | $0.56 | $0.57 | $0.54 |
27 Mar 2024 | $0.55 | $-0.02 | -3.54% | 41,954 | $0.57 | $0.57 | $0.54 |
26 Mar 2024 | $0.57 | $0.00 | 0.00% | 29,795 | $0.55 | $0.57 | $0.55 |
25 Mar 2024 | $0.57 | $-0.01 | -1.75% | 52,800 | $0.57 | $0.57 | $0.57 |
22 Mar 2024 | $0.57 | $-0.01 | -1.72% | 31,757 | $0.58 | $0.58 | $0.57 |
21 Mar 2024 | $0.58 | $0.07 | 13.59% | 111,364 | $0.52 | $0.58 | $0.52 |
20 Mar 2024 | $0.52 | $0.02 | 4.04% | 30,186 | $0.50 | $0.52 | $0.50 |
18 Mar 2024 | $0.50 | $-0.02 | -3.92% | 119,951 | $0.51 | $0.51 | $0.48 |
15 Mar 2024 | $0.51 | $0.01 | 1.98% | 85,271 | $0.51 | $0.53 | $0.50 |
14 Mar 2024 | $0.51 | $0.02 | 4.12% | 57,345 | $0.49 | $0.51 | $0.49 |
13 Mar 2024 | $0.49 | $-0.02 | -4.00% | 91,028 | $0.50 | $0.51 | $0.49 |
12 Mar 2024 | $0.50 | $0.01 | 2.04% | 170,199 | $0.49 | $0.51 | $0.48 |
11 Mar 2024 | $0.49 | $0.02 | 4.26% | 24,003 | $0.48 | $0.49 | $0.48 |
08 Mar 2024 | $0.47 | $0.01 | 2.17% | 52,025 | $0.47 | $0.50 | $0.47 |
07 Mar 2024 | $0.46 | $0.01 | 2.22% | 29,459 | $0.47 | $0.47 | $0.45 |
06 Mar 2024 | $0.45 | $-0.02 | -4.30% | 68,425 | $0.46 | $0.46 | $0.45 |
05 Mar 2024 | $0.47 | $-0.02 | -4.17% | 11 | $0.47 | $0.47 | $0.47 |
04 Mar 2024 | $0.48 | $0.01 | 2.13% | 30,460 | $0.47 | $0.48 | $0.47 |
01 Mar 2024 | $0.47 | $-0.03 | -6.00% | 31,370 | $0.50 | $0.50 | $0.47 |
29 Feb 2024 | $0.50 | $0.00 | 0.00% | 130,609 | $0.49 | $0.50 | $0.46 |
28 Feb 2024 | $0.50 | $0.03 | 6.38% | 79,733 | $0.47 | $0.50 | $0.47 |
27 Feb 2024 | $0.47 | $-0.03 | -6.00% | 181,971 | $0.47 | $0.47 | $0.47 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
28 Feb 2024 | Peter McGregor | Issued | 78,271 | $35,221 |
Rights issue. 665,479 CDIs , as per announcement on 01-03-2024
|
02 Jun 2023 | Steve Wedan | Issued | 1,426,949 | $456,623 |
Issue of options.
|
02 Jun 2023 | Steve Wedan | Expiry | 173,756 | $55,601 |
Options expired.
|
19 May 2023 | Mark Tibbles | Issued | 179,775 | $47,640 |
Issue of securities. CDIs
|
19 May 2023 | Anita Messal | Issued | 168,539 | $44,662 |
Issue of securities. CDIs
|
19 May 2023 | Peter McGregor | Issued | 179,775 | $47,640 |
Issue of securities. 587,028 CDIs
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Peter McGregor | Non-Executive Director | May 2019 |
Mr McGregor has over 30 years' experience in senior finance and management roles, including having been a partner in the investment banking firm of Goldman Sachs JBWere and a managing director in the institutional banking & markets division of Commonwealth Bank of Australia. He is also a former Chief Financial Officer of the ASX50 transport company, Asciano Limited , and Chief Operating Officer of ASX listed Australian Infrastructure Fund Limited. He currently serves as a director of Pivotal Systems Corporation, True Infrastructure Management Pty Ltd and Chain Collective Pty Ltd. He holds a Bachelor of Commerce from the University of Melbourne, is a member of the Australian Institute of Company Directors and a Fellow of the Financial Services Institute of Australasia.
|
Mr Steve Wedan | Chief Executive OfficerPresidentExecutive ChairmanExecutive Director | May 2006 |
Mr Wedan co-founded the Company in 2006 and has served as CEO since that time. He is responsible for the overall management and strategic direction of the Company. He has over 30 years of experience in the medical device industry including design engineering of MRI and ultrasound systems for GE Healthcare, as well as Vice President and Chief Technology Officer for Applied Biometrics Inc. Immediately prior to co-founding Imricor, He founded and operated a technical consulting company, Wedan Technologies Inc., from 2000-2006.He is a member of various international standards committees in the fields of MRI safety and the compatibility of implanted and interventional products in MRI. He currently serves on the Board of Directors of Medical Device Research Forum, Inc. and Water Rescue Innovations, Inc., as well as the Advisory Board of Poiesis Medical, LLC.He holds a Bachelor of Science in Electrical Engineering from Michigan Technological University, and a Master of Science in Electrical Engineering from Marquette University.
|
Mr Mark Tibbles | Non-Executive Deputy ChairmanNon-Executive Director | Sep 2014 |
Mr Tibbles is an entrepreneur, business owner, company director and active venture investor in and advisor to technology, life science and medical device companies. He is currently a Board member of OMEDZA.com, Inc. and Operandi, Inc.; Poiesis Medical LLC's Chief Strategy Officer and Executive Committee Member; an owner and managing member of STEM Fuse, LLC and the Managing Director of Strategic Stage Ventures, LLC. Prior to his current roles, He was a Board member of the Nerdery, LLC as well as an owner and member of Intuitive Technology Group until it was sold in 2017.He was also a President and founder of PRC Consulting, Inc, from 1998 until 2013.He holds a Bachelor of Arts from Oral Roberts University.
|
Ms Anita Messal | Non-Executive Director | Mar 2021 |
Ms. Messal has over 35 years of experience in the health care and benefits industry, most recently as the Chief Integration Officer at AccentCare. She has experience in health plan services, health care delivery, care management, and benefits administration. She has worked with self-funded, fully insured and CMS funded care. Her customers and partners include large and mid-size employers, health plans, insurance carriers, brokers, resellers, enterprise software companies and consumers. She has participated in fund raising from start-up through IPO and sale to strategic buyers and private equity. She has worked in both F100 and start-up companies with experience in public, private and non-profit businesses. Her experience includes working in domestic and international markets, with time spent developing programs and partnerships in the United Kingdom and Europe.
|
Mr Kobe Li | Company Secretary |
-
|
|
Kobe Li | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Citicorp Nominees Pty Limited | 19,376,860 | 12.80% |
HSBC Custody Nominees (Australia) Limited(i) | 12,151,749 | 8.03% |
BNP Paribas Nominees Pty Ltd | 8,870,165 | 5.86% |
Siemens Medical Solutions Usa Inc | 8,384,150 | 5.54% |
Warren G Herreid Ii | 7,819,431 | 5.12% |
BNP Paribas Noms(Nz) Ltd | 6,373,066 | 4.21% |
HSBC Custody Nominees (Australia) Limited(ii) | 3,365,707 | 2.22% |
Kahr Foundation | 2,950,988 | 1.95% |
Steven R Wedan | 2,693,720 | 1.78% |
Bauer Private Equity Fund Vi Llc | 1,696,555 | 1.12% |
Steven R Wedan & Cherri J Wedan Jt Ten | 1,427,373 | 0.94% |
Merrill Lynch (Australia) Nominees Pty Limited | 1,393,726 | 0.92% |
Ronald D Berger | 1,300,000 | 0.86% |
Pacific Premier Trust Cust Fbo Jeffrey J Quinn Ira | 1,288,462 | 0.85% |
Bradica Nominees Pty Ltd | 1,160,421 | 0.77% |
All States Secretariat Pty Limited | 1,000,000 | 0.66% |
Trust Company Cust Fbo Kristin Knight Ira | 961,538 | 0.64% |
Bnp Paribas Noms Pty Ltd | 928,581 | 0.61% |
Fleitman Koppa Investments Llc | 901,530 | 0.60% |
Shear Family Group Pty Ltd | 874,123 | 0.58% |